Table 1 Correlation of clinicopathologic features with METTL3 expression in gastric cancer tissues.
| Â | Numbera | METTL3 expression | P valueb | |
|---|---|---|---|---|
Clinicopathological features | Lowa | Higha | ||
Gender | Â | Â | Â | 0.6497 |
     Male | 68 (78.16%) | 29 (42.65%) | 39 (57.35%) |  |
     Female | 19 (21.84%) | 7 (36.85%) | 12 (63.15%) |  |
Age | Â | Â | Â | 0.8096 |
     ≥65 | 18 (20.69%) | 7 (38.89%) | 11 (61.11%) |  |
     <65 | 69 (79.31%) | 29 (42.03%) | 40 (57.97%) |  |
Stage | Â | Â | Â | 0.0056** |
     I + II | 29 (33.33%) | 18 (62.07%) | 11 (39.93%) |  |
     III + IV | 58 (66.67%) | 18 (31.03%) | 40 (68.97%) |  |
Tumor invasion | Â | Â | Â | 0.5317 |
     T1 or T2 or T3 | 30 (34.48%) | 12 (40.00%) | 18 (60.00%) |  |
     T4 | 57 (65.52%) | 24 (42.11%) | 33 (57.89%) |  |
Lymph node involvement | Â | Â | Â | 0.0251* |
     Yes | 62 (71.26%) | 21 (33.87%) | 41 (66.13%) |  |
     No | 25 (28.74%) | 15 (60.00%) | 10 (40.00%) |  |
Metastasis | Â | Â | Â | 0.0639 |
     M0 | 68 (78.16%) | 32 (47.06%) | 36 (52.94%) |  |
     M1 | 19 (21.84%) | 4 (21.05%) | 15 (78.95%) |  |
Differentiation | Â | Â | Â | 0.2849 |
     Poorly | 47 (54.02%) | 17 (36.17%) | 30 (63.83%) |  |
     Well | 40 (45.98%) | 19 (47.50%) | 21 (52.50%) |  |
Microvascular invasion | Â | Â | Â | 0.0346* |
     Present | 16 (28.07%) | 4 (25.00%) | 12 (75.00%) |  |
     Absent | 41 (71.93%) | 23 (56.10%) | 18 (43.90%) |  |
